These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14507079)

  • 41. The United States Pharmacopeia Veterinary Practitioners' Reporting Program.
    Meyer EK; Becker SC
    J Am Vet Med Assoc; 1996 Feb; 208(3):361-3. PubMed ID: 8575965
    [No Abstract]   [Full Text] [Related]  

  • 42. Safety monitoring in vaccine development and immunization.
    Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML
    Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Adverse events following vaccination reported to the Netherlands Pharmacovigilance Center Lareb in 2004-2006].
    Labadie J; van Grootheest AC
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2738-42. PubMed ID: 18225798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
    Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detecting possible vaccine adverse events in clinical notes of the electronic medical record.
    Hazlehurst B; Naleway A; Mullooly J
    Vaccine; 2009 Mar; 27(14):2077-83. PubMed ID: 19428833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polyarteritis nodosa reports to the vaccine adverse event reporting system (VAERS): implications for assessment of suspected vaccine-provoked vasculitis.
    Begier EM; Langford CA; Sneller MC; Wise RP; Ball R;
    J Rheumatol; 2004 Nov; 31(11):2181-8. PubMed ID: 15517631
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential safety signals and their significance.
    Powers A; Cook GE
    Arch Intern Med; 2012 Jan; 172(1):72-3. PubMed ID: 22082712
    [No Abstract]   [Full Text] [Related]  

  • 48. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines.
    Geier DA; Geier MR
    Brain Dev; 2004 Aug; 26(5):296-300. PubMed ID: 15165669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extra-label drug use: with rights come responsibilities.
    Cleland JL
    J Am Vet Med Assoc; 1996 Sep; 209(5):897-8. PubMed ID: 8790533
    [No Abstract]   [Full Text] [Related]  

  • 50. Assessment and reporting of clinical pharmacology information in drug labeling.
    Spyker DA; Harvey ED; Harvey BE; Harvey AM; Rumack BH; Peck CC; Atkinson AJ; Woosley RL; Abernethy DR; Cantilena LR
    Clin Pharmacol Ther; 2000 Mar; 67(3):196-200. PubMed ID: 10741621
    [No Abstract]   [Full Text] [Related]  

  • 51. Vaccine adverse event monitoring systems across the European Union countries: time for unifying efforts.
    Zanoni G; Berra P; Lucchi I; Ferro A; O'Flanagan D; Levy-Bruhl D; Salmaso S; Tridente G
    Vaccine; 2009 May; 27(25-26):3376-84. PubMed ID: 19200851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse event reporting: essential for science and public trust.
    Verma IM
    Mol Ther; 2001 Aug; 4(2):83. PubMed ID: 11482977
    [No Abstract]   [Full Text] [Related]  

  • 54. Workshop on conflicting guidelines for the use of vaccines.
    Halsey NA; Hall CB
    Pediatrics; 1995 Jun; 95(6):938-41. PubMed ID: 7761228
    [No Abstract]   [Full Text] [Related]  

  • 55. Rx package inserts: redesigned with fewer errors in mind.
    Fass JA; Seamon MJ; Cytacki J
    J Fam Pract; 2007 Jun; 56(6):438-41. PubMed ID: 17543253
    [No Abstract]   [Full Text] [Related]  

  • 56. The vaccine adverse event reporting system.
    Varricchio F
    J Toxicol Clin Toxicol; 1998; 36(7):765-8. PubMed ID: 9865252
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
    Vellozzi C; Burwen DR; Dobardzic A; Ball R; Walton K; Haber P
    Vaccine; 2009 Mar; 27(15):2114-20. PubMed ID: 19356614
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progress in FDA pharmacosurveillance.
    Keller WC
    J Am Vet Med Assoc; 1996 Nov; 209(9):1546-7. PubMed ID: 8899014
    [No Abstract]   [Full Text] [Related]  

  • 59. Monitoring vaccine safety depends on reports from providers.
    Grabenstein JD
    J Am Pharm Assoc (Wash); 1999; 39(6):869. PubMed ID: 10609455
    [No Abstract]   [Full Text] [Related]  

  • 60. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.